"The status report confirms that BSI has now completed the analysis of the data presented to the COC and closed out all concerns with the external clinical and bio-statistical experts."
"The CE Mark review progresses to the next and final phase assessing the post market clinical follow up (PMCF) programe and the post market surveillance (PMS) plan. These post approval plans outline how the OncoSil™ device would be rolled out by OncoSil into the European Market."
"The Company plans to present its PMS/PMCF plans in detail to BSI on November 14th"
From the outside looking in it appears there is a very high chance the CE Mark will be approved later this month, I would have thought if this was the case investors / traders will be positioning themselves to benefit from this decision / annc. and would start to accumulate more shares in the company and you will see the SP rise slowly as we move through November towards the date the decision is made.
It will be interesting to see what impact the presentation on Nov. 14 has on the market and its perception of the OSL business.
OSL Price at posting:
13.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)